With the collaboration, joint customers can seamlessly integrate accurate energy forecasts into power market trading. Photo via amperon.co

In an effort to consolidate and improve energy data and forecasting, a Houston software company has expanded to a new platform.

Amperon announced that it has expanded its AI-powered energy forecasts to Snowflake Marketplace, an AI data cloud company. With the collaboration, joint customers can seamlessly integrate accurate energy forecasts into power market trading. The technology that Amperon provides its customers — a comprehensive, AI-backed data analytics platform — is key to the energy industry and the transition of the sector.

“As Amperon continues to modernize energy data and AI infrastructure, we’re excited to partner with Snowflake to bring the most accurate energy forecasts into a single data experience that spans multiple clouds and geographies," Alex Robart, chief revenue officer at Amperon, says in a news release. "By doing so, we’re bringing energy forecasts to where they will be accessible to more energy companies looking to increase performance and reliability."

Together, the combined technology can move the needle on enhanced accuracy in forecasting that strengthens grid reliability, manages monetary risk, and advances decarbonization.

“This partnership signifies Amperon’s commitment to deliver world-class data-driven energy management solutions," Titiaan Palazzi, head of power and Utilities at Snowflake, adds. "Together, we are helping organizations to easily and securely access the necessary insights to manage risk and maximize profitability in the energy transition."

With Amperon's integrated short-term demand and renewables forecasts, Snowflake users can optimize power markets trading activity and manage load risk.

"Amperon on Snowflake enables us to easily integrate our different data streams into a single unified view," Jack Wang, senior power trader and head of US Power Analysis at Axpo, says. "We value having complete access and control over our analytics and visualization tools. Snowflake allows us to quickly track and analyze the evolution of every forecast Amperon generates, which ultimately leads to better insights into our trading strategy."

Amperon, which recently expanded operations to Europe, closed a $20 million series B round last fall led by Energize Capital and tripled its team in the past year and a half.

In March, Amperon announced that it replatformed its AI-powered energy analytics technology onto Microsoft Azure.

Learn more about the company on the Houston Innovators Podcast episode with Sean Kelly, co-founder and CEO of Amperon.

------

This article originally ran on EnergyCapital.

Alex Robart, Lindsay Huelse, and Joel Cowley are this week's Houston innovators to know. Courtesy photos

3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators couldn't be more varied. Among the movers and shakers in tech in Houston are a serial energy tech entrepreneur, a fitness leader taking her empire mobile, and the leader of a decades old organization looking for the technology of the future.

Alex Robart, CEO of Ambyint

Photo courtesy of Ambyint

Alex Robart was on the lookout for a new tech startup to get involved with when he found Canada-based Ambyint a few years ago. He saw the potential of the artificial intelligence software had on optimizing oil and gas rigs. Now, he's lead the company as CEO and recently oversaw the startup's $15 million series B round.

"We're seeing our customers spend a little more time understanding AI," Robart says on this week's episode of the Houston Innovators Podcast. "More and more boards of mid-sized [exploration and production companies] are challenging their executive teams to do something with AI."

Click here to read more and to listen to the episode.

Lindsay Huelse, founder of The FITT Cycle

Photo courtesy of The FITT Cycle

Houstonian Lindsay Huelse has created a all-in-one approach to fitness and health within her new mobile app, The FITT Cycle , which incorporates fitness routines, nutrition plans, accountability, community, and entrepreneurship.

"Historically, fitness apps are great for memberships," Huelse tells CultureMap. "I wanted to create a platform for returning clients where they could have stability and ditch the diets."

Since its launch in December 2019, Huelse says she has seen a membership growth of almost 2,000 percent, noting that there is no other app with The FITT Cycle's features. She calls it a hybrid of My Fitness Pal, the Peloton App, Facebook communities, and more.

Click here to read more about Huelse and her app.

Joel Cowley, CEO of the Houston Livestock Show and Rodeo

Image via rodeohouston.com

Joel Cowley, CEO of the Houston Livestock Show and Rodeo, speaks very candidly about the rodeo's future technology upgrades. He realizes that there are rodeo goers who won't appreciate the digitization of tickets, carnival passes, etc. or the temporary inconvenience the transition might bring. But he also knows it's necessary and will be worth it to patrons.

"Anytime you do something new, you have to be on guard," Cowley tells InnovationMap. "You have to make sure you are stacked up on capacity — whether that be personnel, scanners, server capacity — because if you're not, it could create a situation from that."

Click here to read more about new tech coming to the rodeo.

Alex Robart, CEO of Ambyint, joins the Houston Innovators Podcast to discuss his plans to grow his company. Photo courtesy of Ambyint

Houston energy tech entrepreneur plans for growth following $15M series B raise

HOUSTON INNOVATORS PODCAST EPISODE 19

After years of having to educate potential customers about the game-changing technology that artificial intelligence can be, Alex Robart, CEO of Ambyint, says it's a different story nowadays.

"We're seeing our customers spend a little more time understanding AI," Robart says on this week's episode of the Houston Innovators Podcast. "More and more boards of mid-sized [exploration and production companies] are challenging their executive teams to do something with AI."

Ambyint, a Calgary-based energy tech startup with its sales and executive teams based in Houston, uses AI to optimize well operations — Robart describes it as a Nest thermostat but for oil rigs. On average, 80 percent of wells aren't optimized — they are either running too fast and not getting enough out of the ground or running too slow and wasting energy, Robart says.

Recently, Ambyint closed its series B investment round at $15 million led by Houston-based Cottonwood Venture Partners led the round with contribution from Houston-based Mercury Fund. Robart says these funds will go to growing their technology to work on a greater variety of wells as well as hire people in both the Canada and Houston offices.

Robart runs Ambyint with his twin brother Chris, who serves as president of the company. The pair have long careers as serial entrepreneurs and even run an energy tech investment company, called Unconventional Capital. Between the two shared companies, the brothers have their own niches.

"We've been really thoughtful about ensuring that we take on different portfolios — we don't really own things jointly. That's been really helpful for us to carve out our own spheres that we own," Robart says."Chris has really become our lead customer-facing person on all things new products."


Ambyint, which has offices in Calgary and Houston, has secured funding from Houston venture capital firms. Getty Images

AI-powered oil and gas startup secures $15 million from Houston VC firms in its series B

Money moves

It's payday for Ambyint. The Canadian startup, which has an office in Houston, has closed its $15 million series B funding round with support from local investors.

Houston-based Cottonwood Venture Partners led the round, and Houston-based Mercury Fund also contributed — as did Ambyint's management team, according to a news release. The money will be used to grow both its Houston and Calgary, Alberta, offices and expand its suite of software solutions for wells and artificial lift systems.

"This funding round is an important milestone for Ambyint, and we're pleased to benefit from unwavering support among our investors to boost Ambyint to its next phase of growth," says Alex Robart, CEO of Ambyint, in the news release. "It is also a proof point for our approach of combining advanced physics and artificial intelligence, deployed on a scalable software infrastructure, to deliver 10 to 20 percent margin gains in a market where meaningful improvements have been hard to achieve."

Ambyint's technology pairs artificial intelligence with advanced physics and subject matter expertise to automate processes on across all well types and artificial lift systems.

Photo via ambyint.com

"Our physics-grounded approach to AI is the difference maker and explains our strong growth in the market as well as our expanding list of marquee customers," says Ryan Benoit, chief technology officer of Ambyint in the release.

The company has mid- to large-sized operators, including Norway-based Equinor and Calgary-based Husky among their customers. According to the release, Ambyint has deployed solutions in every major North American basin.

"Improving margin on producing wells is more important than ever for operators," says Ryan Gurney, managing partner at Cottonwood Venture Partners, in the release. "Ambyint has delivered significant financial benefits for its customers with the application of advanced physics and artificial intelligence, over and above traditional approaches to production optimization. We're excited to see them expand further in the market with solutions that span the entire lifecycle of the well."

According to Ambyint's website, the software promises the ability to increase production levels by 5 percent and lower operating costs by 10 percent.

"Producers flourish — even in a down market — when they understand how exploiting their data effectively can increase productivity and reduce costs," says Adrian Fortino, managing director at Mercury Fund, in the release. "Ambyint turns data into higher yield, more efficient oil and gas production with proven optimization technologies. We're excited to continue our partnership with such a great company and investor syndicate."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.